COST-EFFECTIVENESS OF ESCALATING TO NATALIZUMAB OR SWITCHING AMONG IMMUNOMODULATORS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY

被引：4
|
作者：
Furneri, G. [1 ]
Santoni, L. [2 ]
Ricella, C. [2 ]
Prosperini, L. [3 ]
机构：
[1] EBMA Consulting, Melegnano, Italy
[2] Biogen, Milan, Italy
[3] Sapienza Univ, Dept Neurol & Psychiat 3, Rome, Italy
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2588
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRM71
引用
收藏
页码：A695 / A695
页数：1
相关论文
共 50 条
  • [21] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
    Cavit Boz
    Serkan Ozakbas
    Murat Terzi
    Rana Karabudak
    Serhan Sevim
    Recai Turkoglu
    Aysun Soysal
    Belgin Petek Balcı
    Hüsnü Efendi
    Ömer Faruk Turan
    Nur Yüceyar
    Mehmet Fatih Yetkin
    Serap Zengin Karahan
    Meltem Demirkıran
    Sibel Guler
    Kadriye Agan
    Nefati Kıylıoğlu
    Cavid Baba
    Asli Tuncer
    Mesrure Köseoğlu
    Neurological Sciences, 2023, 44 : 2121 - 2129
  • [22] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
    Boz, Cavit
    Ozakbas, Serkan
    Terzi, Murat
    Karabudak, Rana
    Sevim, Serhan
    Turkoglu, Recai
    Soysal, Aysun
    Balci, Belgin Petek
    Efendi, Husnu
    Turan, Omer Faruk
    Yuceyar, Nur
    Yetkin, Mehmet Fatih
    Karahan, Serap Zengin
    Demirkiran, Meltem
    Guler, Sibel
    Agan, Kadriye
    Kiylioglu, Nefati
    Baba, Cavid
    Tuncer, Asli
    Koseoglu, Mesrure
    NEUROLOGICAL SCIENCES, 2023, 44 (06) : 2121 - 2129
  • [23] Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
    Mehdi Rezaee
    Mohammad Hossein Morowvat
    Maryam Poursadeghfard
    Armin Radgoudarzi
    Khosro Keshavarz
    BMC Health Services Research, 22
  • [24] Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
    Rezaee, Mehdi
    Morowvat, Mohammad Hossein
    Poursadeghfard, Maryam
    Radgoudarzi, Armin
    Keshavarz, Khosro
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [25] THE COST-EFFECTIVENESS OF DISEASE MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Bozkaya, D.
    Livingston, T. P.
    Migliaccio-Walle, K.
    Mehta, S.
    Odom, T.
    VALUE IN HEALTH, 2015, 18 (03) : S283 - S283
  • [26] Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
    Moogeh Baharnoori
    Virender Bhan
    Fraser Clift
    Kimberly Thomas
    Soukaïna Mouallif
    Nicholas Adlard
    Philip Cooney
    François Blanchette
    Barkha P. Patel
    Daniel Grima
    PharmacoEconomics - Open, 2022, 6 : 859 - 870
  • [27] Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
    Baharnoori, Moogeh
    Bhan, Virender
    Clift, Fraser
    Thomas, Kimberly
    Mouallif, Soukaina
    Adlard, Nicholas
    Cooney, Philip
    Blanchette, Francois
    Patel, Barkha P.
    Grima, Daniel
    PHARMACOECONOMICS-OPEN, 2022, 6 (06) : 859 - 870
  • [28] The cost-effectiveness of natalizumab in patients with relapsing multiple sclerosis
    Meyer, K.
    Chiao, E.
    VALUE IN HEALTH, 2007, 10 (03) : A89 - A89
  • [29] Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England
    Hettle, Robert
    Harty, Gerard
    Wong, Schiffon L.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (07) : 676 - 686
  • [30] Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison
    Taheri, Saeed
    Sahraian, Mohammad Ali
    Yousefi, Nazila
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (01) : 71 - 84
12345